Thalys(SH:603716) 智通财经网·2026-01-29 12:41Core Viewpoint - The company, Saily Medical (603716.SH), has announced a projected net loss for the fiscal year 2025, indicating a significant downturn in financial performance [1] Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between -160 million RMB and -209 million RMB [1] - The anticipated net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between -180 million RMB and -230 million RMB [1] Strategic Focus - The company is focusing on high-quality development by accelerating the construction of an integrated diagnostic and treatment technology platform driven by "AI + Smart Healthcare" and "Innovative Biopharmaceuticals" [1] - There is an ongoing effort to consolidate and enhance the company's comprehensive competitiveness in the smart healthcare sector [1]